UMMS Affiliation

MassBiologics

Publication Date

2019-07-29

Document Type

Article Postprint

Disciplines

Amino Acids, Peptides, and Proteins | Bacterial Infections and Mycoses | Complex Mixtures | Enzymes and Coenzymes | Immunoprophylaxis and Therapy | Medicinal Chemistry and Pharmaceutics | Pharmacy and Pharmaceutical Sciences | Therapeutics

Abstract

Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrheal disease in children in developing countries, and there are no licensed vaccines to protect against ETEC. Passive immunization by oral delivery of ETEC-specific secretory IgAs (sIgAs) could potentially provide an alternative approach for protection in targeted populations. In this study, a series of physiochemical techniques and an in vitro gastric digestion model were used to characterize and compare key structural attributes and stability profiles of three anti-heat labile enterotoxin monoclonal antibodies (sIgA1, sIgA2 and IgG1 produced in CHO cells). The mAbs were evaluated in terms of primary structure, N-linked glycan profiles, size and aggregate content, relative apparent solubility, conformational stability, and in vitro antigen binding. Compared to IgG1 mAb, sIgA1 and sIgA2 mAbs showed increased sample heterogeneity, especially in terms of N-glycan composition and the presence of higher molecular weight species. The sIgA mAbs showed overall better physical stability and were more resistant to loss of antigen binding activity during incubation at low pH, 37 degrees C with pepsin. These results are discussed in terms of future challenges to design stable, low-cost formulations of sIgA mAbs as an oral supplement for passive immunization to protect against enteric diseases in the developing world.

Keywords

Secretory immunoglobulin A, enterotoxigenic Escherichia coli, formulation, immunization, immunoglobulin G, oral delivery, physicochemical characterization, stability

Rights and Permissions

This is a PDF file of an accepted manuscript that has been accepted for publication and posted with a 12 month embargo and CC BY-NC-ND license as allowed by the publisher's author rights policy at https://www.elsevier.com/about/policies/sharing.

DOI of Published Version

10.1016/j.xphs.2019.07.018

Source

J Pharm Sci. 2019 Jul 29. pii: S0022-3549(19)30453-8. doi: 10.1016/j.xphs.2019.07.018. [Epub ahead of print] Link to article on publisher's site

Journal/Book/Conference Title

Journal of pharmaceutical sciences

Related Resources

Link to Article in PubMed

PubMed ID

31369743

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Available for download on Wednesday, July 29, 2020

Share

COinS